The purposes of this study were: (1) to test the usefulness of intensive design in detecting the effects of an established antianxiety agent in a single patient studied for a period as brief as 8 weeks and (2) to explore the usefulness of combining intensive and extensive designs by jointly analyzing the results from several similarly treated patients.
Fifteen primarily anxious, psychoneurotic patients aged 21–50 and scoring 17 or more on the Taylor Manifest Anxiety Scale were admitted to the study, and 11 completed the full treatment program. Medications were diazepam 5 mg t.i.d. and a matching placebo, administered under double-blind conditions. Patients were treated for 8 weeks, divided into 42-week blocks. In each block, the patient received diazepam 1 week and placebo the other, with the order in each block determined at random. The patient came weekly for evaluation, including: self-ratings on the Hopkins Symptom Checklist (SCL), global status, global change; reports of occupational and social function; resting pulse; reaction time; psychiatrist's ratings on the Hamilton Anxiety Scale, global status and global change. The patient also reported daily his mood on the Profile of Mood States (POMS). Mean deviations from the general trend for post-diazepam and post-placebo scores on each criterion were compared within patients. Diazepam-placebo differences on each criterion were analyzed between patients.
Criteria that clearly recorded the anti-anxiety effect of diazepam as compared to placebo included the Hamilton Anxiety Scale, the psychiatrist's global status and global change ratings, the SCL Anxiety and Somatization Scales, and the POMS Anxiety Scale. Other criteria that showed a reliable diazepam effect included SCL Depression (decrease), POMS Vigor (increase), POMS Fatigue (decrease), SCL Anger (increase), and reaction time (increase).
The most sensitive criteria distinguished diazepam from placebo even when results were considered only from the first 6 patients during their first 4 weeks of treatment — a total of 24 patient weeks of treatment. The factors contributing to the sensitivity of this design were investigated and discussed.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bellak, L., Chassan, J. B.: An approach to the evaluation of drug effect during psychotherapy: A double-blind study of the single case. J. nerv. ment. Dis. 139, 20–40 (1964)
Chassan, J. B.: Research design in clinical psychology and psychiatry. New York: Appleton-Century-Crofts 1967
Chassan, J. B.: Intensive design in medical research. Pharmacol. Ther. B 1, 139–148 (1975)
Derogatis, L. R., Bonato, R. R., Yang, K. C.: The power of IMPS in psychiatric drug research. Arch. gen. Psychiat. 19, 689–699 (1968)
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., Covi, L.: The Hopkins symptom checklist (HSCL): A self-report symptom inventory. Behav. Sci. 19, 1–15 (1974)
DiMascio, A.: The effects of benzodiazepines on aggression: Reduced or increased? In: The benzodiazepines, S. Garattini, E. Mussini, and L. O. Randall, eds. New York: Raven Press 1973
Eysenck, H. S., Eysenck, S. B. G.: A Manual for the Eysenck personality inventory. San Diego, Calif.: Education and Industrial Testing Service 1968
Hamilton, M.: The assessment of anxiety states by rating. Brit. J. med. Psychol. 32, 50–55 (1959)
Jacobs, M. A., Globus, G., Heim, E.: Reduction in symptomatology in ambulatory patients. Arch. gen. Psychiat. 15, 45–53 (1966)
Janke, W., Debus, G.: Experimental studies on antianxiety agents with normal subjects: Methodological considerations and review of the main effects. In: Psychopharmacology: A review of progress 1957–1967. D. H. Efron, J. O. Cole, J. Levine, and J. R. Wittenborn, eds., PHS Publ. No. 1836. Washington, D.C.: U.S. Government Printing Office 1968
Kellner, R.: Part 2. Improvement criteria in drug trials with neurotic patients. Psychol. Med 2, 73–80 (1972)
Kellner, R., Wilson, R. M., Muldawer, M. D., Pathak, D.: Anxiety in schizophrenia: The responses to chlordiazepoxide in an intensive design study. Arch. gen. Psychiat. 32, 1246–1254 (1975)
King, H. E.: Psychomotor aspects of mental disease. Cambridge: Harvard Univ. 1954
Klein, D. F., Davis, J. M.: Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins 1969
Lipman, R. S., Covi, L., Rickels, K., Uhlenhuth, E. H., Lazar, R.: Selected measures of change in outpatient drug evaluation. In: Psychopharmacology: A review of progress 1957–1967. D. H. Efron, J. O. Cole, J. Levine, and J. R. Wittenborn, eds., PHS Publ. No. 1836, Washington, D.C. U.S. Government Printing Office 1968
McNair, D. M., Fisher, S., Kahn, R. J., Droppleman, L. F.: Drug-personality interaction in intensive outpatient treatment. Arch. gen. Psychiat. 22, 128–135 (1970)
McNair, D. M., Lorr, M., Droppleman, L. F.: EITS manual for the profile of mood states. San Diego, Calif.: Educational and Industrial Testing Service 1971
McPherson, F. M., Le Gassicke, J.: A single patient, self-controlled and self-recorded trial of WY 3498. Brit. J. Psychiat. 111, 149–154 (1965)
Overall, J. E., Hollister, L. E., Dalal, S. N.: Psychiatric drug research: Sample size requirements for one and two raters. Arch. gen. Psychiat. 16, 152–161 (1967)
Rickels, K.: Antineurotic agents: Specific and non-specific effects. In: Psychopharmacology: A review of progress 1957–1967, D. H. Efron, J. O. Cole, J. Levine, and J. R. Wittenborn, eds., PHS Publ. No. 1836. Washington D.C.: U.S. Government Printing Office 1968
Rickels, K., Downing, R. W.: Minor tranquilizers in anxiety: Some prognostic indicators. Presented at an International Symposium on “Relaxation therapy for psychosomatic disorders,” St. Moritz, January 11–13, 1971
Rickels, K., McLaughlin, B. E.: Sample size in psychiatric drug research. Clin. Pharmacol. Ther. 9, 631–634 (1968)
Taylor, J. A.: A personality scale of manifest anxiety. J. abnorm. Soc. Psychol. 48, 285–290 (1953)
About this article
Cite this article
Uhlenhuth, E.H., Turner, D.A., Purchatzke, G. et al. Intensive design in evaluating anxiolytic agents. Psychopharmacology 52, 79–85 (1977). https://doi.org/10.1007/BF00426604
- Experimental design
- Reaction time